Summary
Vertex Pharmaceuticals Inc. (VRTX) reported its second-quarter and first-half financial results for the period ending June 30, 2021. The company experienced a significant increase in product revenues, driven by strong performance of its cystic fibrosis (CF) treatments, TRIKAFTA/KAFTRIO, particularly in Europe and the U.S. However, net income saw a substantial decrease compared to the prior year, largely due to a $900 million upfront payment made to CRISPR Therapeutics in connection with an amendment to their collaboration agreement for the gene-editing therapy CTX001. Despite the hit to net income from the CRISPR payment, Vertex maintains a strong liquidity position with over $6.7 billion in cash, cash equivalents, and marketable securities. The company continues to invest heavily in research and development, with a particular focus on expanding its CF franchise and advancing its pipeline of cell and gene therapies for other serious diseases like sickle cell disease, type 1 diabetes, and Duchenne muscular dystrophy. Investors should note the significant R&D investment and the ongoing progress in pipeline development alongside the core CF business.
Financial Highlights
48 data points| Revenue | $1.79B |
| Cost of Revenue | $228.00M |
| Gross Profit | $1.57B |
| R&D Expenses | $1.41B |
| SG&A Expenses | $194.60M |
| Operating Expenses | $1.83B |
| Operating Income | -$37.90M |
| Net Income | $67.00M |
| EPS (Basic) | $0.26 |
| EPS (Diluted) | $0.26 |
| Shares Outstanding (Basic) | 259.00M |
| Shares Outstanding (Diluted) | 261.00M |
Key Highlights
- 1Product revenues increased by 18% year-over-year in Q2 2021 to $1.79 billion, driven by TRIKAFTA/KAFTRIO's strong uptake.
- 2Net income decreased by 92% in Q2 2021 to $66.9 million, primarily due to a $900 million upfront payment to CRISPR.
- 3Cash, cash equivalents, and marketable securities stood at $6.71 billion as of June 30, 2021, indicating a strong liquidity position.
- 4Research and development expenses surged by 234% in Q2 2021 to $1.41 billion, largely driven by the CRISPR collaboration payment.
- 5Vertex received FDA approval for TRIKAFTA in children aged 6-11 years and Health Canada authorization for TRIKAFTA for ages 12+.
- 6The company advanced its CTX001 gene-editing therapy program for sickle cell disease and beta thalassemia, with promising early data.
- 7A new $1.5 billion share repurchase program was authorized in June 2021.